NCT05811000View on ClinicalTrials.gov

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

February 24, 2021

Study Completion Date

August 13, 2024

Conditions
Mild Alzheimer Disease
Interventions
DRUG

PM012

PM012 650 mg tablet drug

DRUG

PM012 Placebo

PM012 tablet placebo

DRUG

Donepezil

Aricept 5 mg (donepezil hydrochloride) drug

DRUG

Donepezil placebo

Aricept 5 mg (donepezil hydrochloride) placebo

Trial Locations (1)

04784

RECRUITING

Mediforum, Seoul

Sponsors
All Listed Sponsors
collaborator

LSK Global Pharma Services Co. Ltd.

UNKNOWN

lead

Mediforum Ltd., Co.

INDUSTRY

NCT05811000 - A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease | Biotech Hunter | Biotech Hunter